【上海医药(02607.HK)：盐酸维拉帕米注射液通过仿制药一致性评价】智通财经APP讯，上海医药(02607.HK)发布公告，近日，公司下属上海禾丰制药有限公司(简称“上药禾丰”)的盐酸维拉帕米注射液收到国家药品监督管理局颁发的《药品补充申请批准通知书》(通知书编号：2025B03892)，该药品通过仿制药质量和疗效一致性评价。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.